Regulatory T cells induced by intravenous immunoglobulin therapy through expression of B7-2

1997 ◽  
Vol 56 (1-3) ◽  
pp. 371
Author(s):  
T Okamoto
2013 ◽  
Vol 172 (6) ◽  
pp. 833-837 ◽  
Author(s):  
Yu Hirabayashi ◽  
Yoshiyuki Takahashi ◽  
Yinyan Xu ◽  
Kazuyuki Akane ◽  
Itzel Bustos Villalobos ◽  
...  

2021 ◽  
Author(s):  
Nana Wang ◽  
Zhongyue Chen ◽  
Fan Zhang ◽  
Qianwen Zhang ◽  
Ling Sun ◽  
...  

Abstract Background: Intravenous immunoglobulin (IVIG) is widely used to treat Kawasaki disease (KD). However, the mechanisms by which it reduces systemic inflammation are not completely understood. Dendritic cells (DCs) and T cells play critical roles in the pathogenic processes of immune disorders. Assessing the quantity of DC subsets and T cells and identifying functional molecules present on these cells, which provide information about KD, in the peripheral blood may provide new insights into the mechanisms of immunoglobulin therapy. Methods: In total, 54 patients with KD and 27 age-matched healthy controls (HCs) were included in this study. The number, percentage, and phenotype of DC subsets and CD4+ T cells in peripheral blood were analysed through flow cytometry.Results: Patients with KD exhibited fewer peripheral DC subsets and CD4+ T cells than HCs. Human leucocyte antigen-DR (HLA-DR) expression was reduced on myeloid DCs (CD1c+ mDCs), whereas that on plasmacytoid DCs (pDCs) did not change significantly. Both pDCs and CD1c+ mDCs displayed significantly reduced expression of co-stimulatory molecules, including CD40, CD86. Expression of T-cell immunoglobulin and mucin domain 3 (TIM-3) was increased on CD4+ T cells. No significant differences were observed concerning the quantity and phenotype of DC subsets and CD4+ T cells in patients with KD with and without coronary artery lesions. Importantly, these altered quantity and phenotypes on DC subsets and CD4+ T cells were restored to a great extent after IVIG treatment. T helper (Th) subsets including Th1 and Th2 among CD4+ T cells did not show alteration pre- and post-IVIG treatment, although the Th1-related cytokine IFN-γ level increased dramatically in patients with KD pre-IVIG treatment.Conclusions: pDCs and CD1c+ DCs presented an immature or tolerant phenotype in acute stages of KD, IVIG treatment restored the quantity and functional molecules of DCs and CD4+ T cells to distinct levels, indicating the involvement of DCs and CD4+ T cells in the inflammation in KD. The findings provide insights into the immunomodulatory actions of IVIG.


2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Wenhua Xu ◽  
Mingshan Ren ◽  
Swagata Ghosh ◽  
Kai Qian ◽  
Zhaofeng Luo ◽  
...  

Myasthenia gravis (MG) is a CD4+ T cell-dependent autoimmune disease resulting from aberrant immune response mediated by circulating autoantibodies at the neuromuscular junction. Intravenous immunoglobulin (IVIg) is an expensive and commonly used immunotherapeutic approach to treat patients with MG. The mechanisms of actions involved in IVIg treatment, however, remain to be investigated. In an effort to examine the roles of various subsets of CD4+ T cells in the periphery blood of MG and uncover the mechanisms that contribute to the therapeutical effects of IVIg, we first demonstrated that a subset of CD4+ T cells, CTLA-4-expressing regulatory T (Treg) cells, were underrepresented and functionally defective in MG patients. The dynamic profiling during the IVIg therapy course further revealed an inverse relationship between the frequency of CTLA-4+ Treg and the quantitative MG (QMG) score that represents disease severity. Our mechanistic studies indicated that IVIg expands CTLA-4-Treg cells via modulating antigen-presenting dendritic cells (DCs). To determine the molecular defects of CTLA-4 in abnormities of Treg in MG patients, we demonstrated hypermethylation at -658 and -793 CpGs of CTLA-4 promoter in MG Tregs. Interestingly, IVIg therapy significantly reduced the methylation level at these two sites in MG patients. Overall, our study may suggest a role of CTLA-4 in functionally defected Treg cells in MG and its actions involved in IVIg therapy.


2012 ◽  
Vol 18 (1) ◽  
pp. 26-31
Author(s):  
Eun Kyeong Yeon ◽  
A Young Park ◽  
Sanghoon Chae ◽  
Seung Soo Kim ◽  
Kyeong Bae Park ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document